Supernus Pharmaceuticals Inc
SUPN51.570USD
-0.200-0.39%
Handelsschluss 12/26, 16:00（ET）Kurse um 15 Minuten verzögert
2.95BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Supernus Pharmaceuticals Inc Unternehmen
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company’s diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. It is also developing a range of product candidates for CNS disorders. Its commercial products that it markets include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC and ONAPGO. Its ONAPGO injection is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. It also offers ZURZUVAE (zuranolone) capsules CIV, which is a U.S. FDA-approved oral medicine indicated for the treatment of adults with postpartum depression.
Supernus Pharmaceuticals Inc Informationen
BörsenkürzelSUPN
Name des UnternehmensSupernus Pharmaceuticals Inc
IPO-datumDec 28, 2010
CEOKhattar (Jack A)
Anzahl der mitarbeiter674
WertpapierartOrdinary Share
GeschäftsjahresendeDec 28
Addresse9715 Key West Avenue
StadtROCKVILLE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl20850
Telefon13018382500
Websitehttps://www.supernus.com
BörsenkürzelSUPN
IPO-datumDec 28, 2010
CEOKhattar (Jack A)
Führungskräfte von Supernus Pharmaceuticals Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jack A. Khattar
Mr. Jack A. Khattar
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
2.21M
+2.76%
Mr. Frederick M. Hudson, CPA
Mr. Frederick M. Hudson, CPA
Independent Director
Independent Director
46.31K
-13.87%
Dr. Carrolee Barlow, M.D., Ph.D.
Dr. Carrolee Barlow, M.D., Ph.D.
Independent Director
Independent Director
22.57K
--
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Independent Director
Independent Director
18.68K
--
Mr. Frank Mottola
Mr. Frank Mottola
Chief Operating Officer, Chief Technology Officer
Chief Operating Officer, Chief Technology Officer
15.15K
--
Dr. Padmanabh P. Bhatt, Ph.D.
Dr. Padmanabh P. Bhatt, Ph.D.
Senior Vice President - Intellectual Property, Chief Scientific Officer
Senior Vice President - Intellectual Property, Chief Scientific Officer
13.37K
+5.27%
Dr. Jonathan Rubin, M.D.
Dr. Jonathan Rubin, M.D.
Senior Vice President, Chief Medical Officer - Research and Development
Senior Vice President, Chief Medical Officer - Research and Development
10.67K
+10.74%
Mr. Timothy C. (Tim) Dec, CPA
Mr. Timothy C. (Tim) Dec, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
901.00
-92.89%
Mr. Charles W. Newhall, III
Mr. Charles W. Newhall, III
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Bethany L. Sensenig
Ms. Bethany L. Sensenig
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jack A. Khattar
Mr. Jack A. Khattar
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
2.21M
+2.76%
Mr. Frederick M. Hudson, CPA
Mr. Frederick M. Hudson, CPA
Independent Director
Independent Director
46.31K
-13.87%
Dr. Carrolee Barlow, M.D., Ph.D.
Dr. Carrolee Barlow, M.D., Ph.D.
Independent Director
Independent Director
22.57K
--
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Independent Director
Independent Director
18.68K
--
Mr. Frank Mottola
Mr. Frank Mottola
Chief Operating Officer, Chief Technology Officer
Chief Operating Officer, Chief Technology Officer
15.15K
--
Dr. Padmanabh P. Bhatt, Ph.D.
Dr. Padmanabh P. Bhatt, Ph.D.
Senior Vice President - Intellectual Property, Chief Scientific Officer
Senior Vice President - Intellectual Property, Chief Scientific Officer
13.37K
+5.27%
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Oct 6
Währung: USDAktualisiert: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Net product sales-Qelbree
77.55M
46.87%
Net product sales - GOCOVRI
36.66M
22.16%
Net product sales-APOKYN
12.82M
7.75%
Net product sales- Oxtellar XR
11.64M
7.03%
Net product sales- Trokendi XR
11.19M
6.77%
Andere
15.60M
9.43%
Nach RegionUSD
Name
Umsatz
Anteil
United States
165.45M
100.00%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Net product sales-Qelbree
77.55M
46.87%
Net product sales - GOCOVRI
36.66M
22.16%
Net product sales-APOKYN
12.82M
7.75%
Net product sales- Oxtellar XR
11.64M
7.03%
Net product sales- Trokendi XR
11.19M
6.77%
Andere
15.60M
9.43%
Aktionärsstatistik
Aktualisiert: Sun, Nov 16
Aktualisiert: Sun, Nov 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
13.33%
The Vanguard Group, Inc.
10.52%
Dimensional Fund Advisors, L.P.
5.24%
Armistice Capital LLC
4.95%
Nomura Investment Management Business Trust
4.42%
Andere
61.56%
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
13.33%
The Vanguard Group, Inc.
10.52%
Dimensional Fund Advisors, L.P.
5.24%
Armistice Capital LLC
4.95%
Nomura Investment Management Business Trust
4.42%
Andere
61.56%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
51.64%
Investment Advisor/Hedge Fund
25.75%
Hedge Fund
20.25%
Individual Investor
4.29%
Research Firm
3.21%
Pension Fund
1.48%
Venture Capital
1.19%
Bank and Trust
0.63%
Sovereign Wealth Fund
0.10%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
575
60.19M
104.97%
-3.36M
2025Q2
565
63.61M
113.46%
-2.51M
2025Q1
587
64.77M
115.71%
-2.86M
2024Q4
569
65.17M
116.92%
-2.59M
2024Q3
551
65.02M
117.72%
-2.14M
2024Q2
536
63.49M
115.33%
-2.27M
2024Q1
535
61.47M
111.83%
-3.83M
2023Q4
534
61.60M
112.54%
-3.30M
2023Q3
534
60.88M
111.42%
-4.46M
2023Q2
534
61.11M
111.93%
-1.60M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
8.01M
14.29%
-191.39K
-2.33%
Jun 30, 2025
The Vanguard Group, Inc.
6.19M
11.04%
+41.36K
+0.67%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
3.02M
5.39%
+117.48K
+4.05%
Jun 30, 2025
Armistice Capital LLC
4.81M
8.58%
-384.00K
-7.39%
Jun 30, 2025
Nomura Investment Management Business Trust
2.76M
4.93%
+62.46K
+2.31%
Jun 30, 2025
Khattar (Jack A)
2.15M
3.84%
+54.63K
+2.60%
Sep 30, 2025
State Street Investment Management (US)
2.21M
3.94%
+63.21K
+2.95%
Jun 30, 2025
Renaissance Technologies LLC
1.66M
2.95%
+69.60K
+4.39%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
AdvisorShares Psychedelics ETF
7.48%
iShares Neuroscience and Healthcare ETF
3.83%
Invesco Pharmaceuticals ETF
3.32%
State Street SPDR S&P Pharmaceuticals ETF
3.11%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.21%
Invesco S&P SmallCap Health Care ETF
1.89%
Pacer US Small Cap Cash Cows Growth Leaders ETF
1.63%
Lattice Hartford Multifactor Small Cap ETF
1.3%
iShares U.S. Pharmaceuticals ETF
1.14%
First Trust Multi-Manager Small Cap Opportunities ETF
0.68%
Mehr Anzeigen
AdvisorShares Psychedelics ETF
Anteil7.48%
iShares Neuroscience and Healthcare ETF
Anteil3.83%
Invesco Pharmaceuticals ETF
Anteil3.32%
State Street SPDR S&P Pharmaceuticals ETF
Anteil3.11%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Anteil2.21%
Invesco S&P SmallCap Health Care ETF
Anteil1.89%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Anteil1.63%
Lattice Hartford Multifactor Small Cap ETF
Anteil1.3%
iShares U.S. Pharmaceuticals ETF
Anteil1.14%
First Trust Multi-Manager Small Cap Opportunities ETF
Anteil0.68%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Supernus Pharmaceuticals Inc?
Die fünf größten Anteilseigner von Supernus Pharmaceuticals Inc sind:
BlackRock Institutional Trust Company, N.A. hält 8.01M Aktien, was 14.29% der Gesamtaktien entspricht.
The Vanguard Group, Inc. hält 6.19M Aktien, was 11.04% der Gesamtaktien entspricht.
Dimensional Fund Advisors, L.P. hält 3.02M Aktien, was 5.39% der Gesamtaktien entspricht.
Armistice Capital LLC hält 4.81M Aktien, was 8.58% der Gesamtaktien entspricht.
Nomura Investment Management Business Trust hält 2.76M Aktien, was 4.93% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 8.01M Aktien, was 14.29% der Gesamtaktien entspricht.
The Vanguard Group, Inc. hält 6.19M Aktien, was 11.04% der Gesamtaktien entspricht.
Dimensional Fund Advisors, L.P. hält 3.02M Aktien, was 5.39% der Gesamtaktien entspricht.
Armistice Capital LLC hält 4.81M Aktien, was 8.58% der Gesamtaktien entspricht.
Nomura Investment Management Business Trust hält 2.76M Aktien, was 4.93% der Gesamtaktien entspricht.
Was sind die drei wichtigsten Anteilseigner-Typen von Supernus Pharmaceuticals Inc?
Die drei wichtigsten Anteilseigner-Typen von Supernus Pharmaceuticals Inc sind:
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Dimensional Fund Advisors, L.P.
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Dimensional Fund Advisors, L.P.
Wie viele Institutionen halten Anteile an Supernus Pharmaceuticals Inc (SUPN)?
Mit Stand vom 2025Q3 halten 575 Institutionen Anteile an Supernus Pharmaceuticals Inc, mit einem Gesamtmarktwert von etwa 60.19M, was 104.97% der Gesamtanteile entspricht. Im Vergleich zum 2025Q2 ist der institutionelle Aktienbesitz um -8.49% gestiegen.
Was ist die größte Einnahmequelle von Supernus Pharmaceuticals Inc?
Am FY2025Q2 erzielte das Geschäft mit Net product sales-Qelbree für Supernus Pharmaceuticals Inc den höchsten Umsatz in Höhe von 77.55M, was 46.87% des Gesamtumsatzes entspricht.
